Filing Details

Accession Number:
0001209191-15-032248
Form Type:
4
Zero Holdings:
No
Publication Time:
2015-04-03 16:09:13
Reporting Period:
2015-04-01
Filing Date:
2015-04-03
Accepted Time:
2015-04-03 16:09:13
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1305253 Celladon Corp CLDN Biological Products, (No Disgnostic Substances) (2836) 330971591
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1590702 K Ryan Takeya 11988 El Camino Real Ste. 650
San Diego CA 92130
Vp, Manufacturing No Yes No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2015-04-01 4,444 $1.12 5,876 No 4 M Direct
Common Stock Disposition 2015-04-01 4,444 $19.13 1,432 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 M Direct
No 4 S Direct
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Common Stock Stock option (right to buy) Disposition 2015-04-01 4,444 $0.00 4,444 $1.12
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
139,574 2013-01-27 2022-06-14 No 4 M Direct
Footnotes
  1. The amount includes shares purchased under Celladon Corporation's employee stock purchase plan prior to the reported transaction.
  2. The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 plan adopted by the reporting person on September 15, 2014.
  3. The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $18.84 to $19.36 per share, inclusive. The reporting person undertakes to provide to Celladon Corporation, any security holder of Celladon Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.
  4. 25% of the shares subject to the option vested and became exercisable on the one year anniversary of January 27, 2012 (the "Vesting Commencement Date"), and 1/48th of the shares vest in equal monthly installments thereafter, over the remaining three years.